ArticleHead & neck2026
Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe standard-of-care for advanced periauricular cutaneous squamous cell carcinoma (pCSCC) is surgery and adjuvant radiation therapy. Neoadjuvant immunotherapy recently demonstrated high pathologic response rates in patients with resectable pCSCC.
methodsThis retrospective review was conducted at a tertiary cancer center and included patients with pathologically confirmed pCSCC within the periauricular area treated with curative-intent surgery with or without neoadjuvant immunotherapy from 2005 to 2025. Patients who received neoadjuvant immunotherapy followed by surgery were age- and stage-matched to those who underwent upfront surgery. The primary outcomes were event-free survival (EFS) and overall survival (OS), estimated using the Kaplan-Meier method.
resultsThe study included 85 patients. Twenty-four (28.2%) of whom received neoadjuvant immunotherapy and 61 (71.7%) underwent upfront surgery. The two cohorts had no differences in staging or disease burden at presentation. Forty-eight patients presented with recurrent disease, equally distributed among the groups (57% vs. 54%, p > 0.05). Patients receiving neoadjuvant immunotherapy had longer median EFS than those undergoing upfront surgery (5.9 vs. 3.4 years; hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.13-0.84; p = 0.02). Specifically, EFS at 2 years was 87% in the neoadjuvant group compared with 55% in the upfront surgery group (p < 0.05). Median OS was also longer in the neoadjuvant group (not met vs. 4.4 years; HR, 0.32; 95% CI, 0.11-0.90; p = 0.031).
conclusionsNeoadjuvant immunotherapy improved survival outcomes in patients with advanced resectable pCSCC. These findings underscore the importance of including this patient population in upcoming randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.